{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nalisertib: Given PO\n\nrituximab: Given IV\n\nlaboratory biomarker analysis: Laboratory correlative studies will be performed","id":"OG000","title":"Cohort A (Alisertib, Rituximab)"},{"description":"Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nalisertib: Given PO\n\nrituximab: Given IV\n\nlaboratory biomarker analysis: Laboratory correlative studies will be performed","id":"OG001","title":"Cohort B (Alisertib, Rituximab)"}],"paramType":"NUMBER","populationDescription":"2 course endpoints only apply to Cohort B, since Cohort B only received 2 courses of the interested drug","reportingStatus":"POSTED","timeFrame":"6 weeks (2 courses)","title":"Complete Response Rate (CR)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}